

# **Innovate** *differently*

Accelerating patient access to optimal care through unique insights and agile, technology-enabled research partnerships





# **Experience the power of** an integrated approach

Û

Genesis Research Group is a global organization that empowers life science companies to **innovate differently** by fundamentally transforming the way they engage with research partners.

Through the integration of strategic acumen, robust stakeholder insights, data-agnostic expertise, and a revolutionary engagement model, we deliver real-world evidence, HEOR, and market access solutions that enable our partners to anticipate and address the evolving needs of payers, regulators, and stakeholders.

Since our founding in 2009, our focus has been on developing a better way to support pharmaceutical, biotech, and medical device companies. Our current model is the result of listening to our clients and evolving the organization to meet their continued need for scientific rigor, efficiency, and flexibility. Our agile, technology-enabled research partnerships are the result.

Our vision is to redefine healthcare research and accelerate patient access to optimal care by delivering accelerated excellence through agile, technology-enabled research partnerships.

#### **TECHNOLOGY-ENABLED RESEARCH**

### Where technology meets expertise

EVIDAI

Supported by specialist teams, our unique agile technology platforms such as EVID AI and **RPR<sup>™</sup>** help us to provide our clients with impactful insights at an accelerated rate.

RPR is an agile, on-demand platform that leverages a network of 3500+ stakeholders across 65+ countries to provide clients with rapid, high-quality insights via direct, automated stakeholder/payer engagement, including the ability to ask follow-up questions.

**EVID AI** is an AI-powered literature review platform that represents the world's largest, curated, up-to-date database of healthcare literature results. Our dedicated evidence synthesis teams use this platform to provide clients with unparalleled support.

3 **OVERVIEW** 

4-5 FLEXIBLE INTEGRATED TEAMS (FIT)

6-7 **REAL-WORLD EVIDENCE** 

8-9 **RPR AND ACCESS & PRICING** 

10-11 HEALTH ECONOMICS AND OUTCOMES RESEARCH



"Genesis Research Group is a valued, relied upon, and trusted partner on our most important deliverables." Senior Director, Real-world Evidence



**Our Integrated Evidence Planning (IEP)** platforms are online evidence planning, integration, and management solutions that help clients address the challenges of evidence organization and communication.

Our interdisciplinary scientific team designs, builds, and implements fit-for-purpose dashboards that transform complex data into digestible insights that are rigorous, transparent, and impactful.

FLEXIBLE INTEGRATED TEAMS

# **Research partnerships reimagined**

Our Flexible Integrated Team (FIT) engagement model represents a paradigm shift in how companies engage with research partners.

FIT

Contracting through a statement of work (SOW) can be the most appropriate choice and we successfully deliver hundreds of projects on that basis. The revolutionary FIT mode of engagement, however, provides a far more **agile** alternative.

#### Fit-for-purpose expertise, when and where you need it

- A FIT engagement provides a dedicated, cross-functional team that **integrates seamlessly** within your own to fill experience gaps or supplement existing resources.
- Together, we select the right team size and mix of HEOR, market access, and RWE expertise to meet your initial need.
- The size and composition of your team can then evolve or **pivot quickly** to meet your changing needs without the costly delays involved in adjusting a statement of work.

As a trusted extension of your organization, our team becomes your team.

scientists and other experts ready to support your work 48

FIT engagements currently in place



2mo the typical length of a FIT engagement prior to renewal

### **Evolving to FIT your changing evidence needs**

The size and composition of your Flexible Integrated Team can be adjusted over time to match your changing evidence needs, but a single strategic client lead manages your account throughout the engagement.



### How would a FIT engagement benefit you?



### Agility

Capacity

new project without contractual adjustment.

<u> </u>	Դ
=	
=	<u>-</u>

With ongoing access to all our solutions, you can benefit from the precise expertise, thought leadership, insights, and technology platforms you need when you need them. The extensive depth and breadth of our RWE, HEOR, and market access expertise is yours to leverage.



In addition to reducing the time and costs involved in contractual updates, FIT engagements offer exceptional value due to the continuity of workflow and efficiencies derived from our experts being immersed in your strategy, personnel, and processes.

"Your partnership has been invaluable. You have filled the gaps within our team and your work has been foundational to our overall access strategy."

ASSOCIATE DIRECTOR, GLOBAL MARKET ACCESS

#### The composition and size of your **dedicated**, **cross-functional team** is customized precisely to your requirements. It then evolves as your product develops or pivots quickly to meet new strategic needs or even a completely

#### **REAL-WORLD EVIDENCE SOLUTIONS**

# **Optimize your RWE with our** rigorous data-agnostic approach

From early development to commercialization, you need the right real-world data (RWD) to support your real-world evidence (RWE) needs.

After 14 years of refining our services, we have:

- Curated an international team of 100+ RWE specialists in epidemiology, biostatistics, pharmacoepidemiology and safety, and analytics and automation.
- Become well-versed in the strengths and limitations of global RWD across therapeutic areas, having utilized 40+ unique data sources on behalf of clients.
- Secured impactful results for hundreds of companies, and developed a powerful reputation for scientific rigor and methodological expertise.
- Contributed **peer-reviewed publications** across a wide range of therapeutic areas, including in oncology, cardiology, neurology, infectious diseases, respiratory, and hematology.
- Delivered comprehensive RWE solutions, including study design methodology, data landscaping assessments and selection expertise, research medical coding support, and dashboards and visualizations.

#### Epidemiology

Providing scientific leadership in planning, executing, interpreting, and communicating real-world evidence.

#### Biostatistics

Applying novel statistical methodology, developing statistical analysis plans, and interpreting results.

#### Analytics

Leveraging tech-enabled data programming and statistical analysis to generate robust insights.

#### Pharmacoepi and Safety

Offering expertise in the design and application of studies for regulatory purposes, including external control arms and safety.

### Benefit from RWE expertise that is:

#### **Data-agnostic**

Effective

Untied to specific data sources and with extensive knowledge of global data, we are ideally placed to provide expert, independent advice and impactful real-world evidence services and studies.

### Fit-for-purpose

The depth of our dataset expertise guarantees that only your precise evidence needs drive our selection of real-world data.

Our real-world evidence experts are highly experienced at

delivering confirmatory analyses across a variety of global datasets.

### A better way to visualize and communicate your evidence

Within our real-world evidence offering, you can also leverage fit-for-purpose **dashboards** to transform complex data into digestible insights that are rigorous, transparent, and impactful.

Our integrated team of outcomes research and data scientists, programmers, and visualization analysts design, build, and implement dashboards that are customized precisely to your requirements.

"We are really impressed with the efficiency and quality of the work, your leadership skills, and the extra efforts you've made to ensure the results are absolutely accurate." SENIOR DIRECTOR, REAL-WORLD EVIDENCE



#### **Navigating external** control arms (ECAs)

Our track record of scientific leadership within ECA design and execution is wellestablished, having successfully supported numerous projects, from early feasibility and data selection to regulatory/HTA submission.

With many years' experience developing protocols and statistical analysis plans for regulatory review, our team is able to anticipate and address regulator concerns.





**RPR™ STAKEHOLDER INSIGHTS** 



# A simple, powerful approach to stakeholder engagement

**RPR<sup>™</sup> is an agile, on-demand platform** that enables us to conduct robust and insightful research on your behalf through direct stakeholder/payer engagement. RPR<sup>™</sup> allows clients to test and refine individual market access or HEOR strategies, or even to validate entire evidence generation plans.

Answers when you need them

from stakeholders/payers who can easily access and participate in surveys via our secure online portal.

- Double-blinded and secure to ensure compliance with market standards.
- Agile stakeholder engagement including a dynamic ability for our experts to interact with stakeholders and ask clarificatory and follow-up questions.
- Question development support from a highly qualified team of expert consultants who help

develop insightful questions based on your project goals. Project dashboard and insight reports

- managed by relevant experts who analyze the data and provide robust insight reports with actionable recommendations.
- Flexible credit-based model

allows you to go straight to field for any initiative without the need for additional time-consuming contracting.



"I particularly like the ability to ask follow-up questions... it produces much richer insights for decision-making."

- HEAD OF MARKET ACCESS. GLOBAL PHARMACEUTICAL

#### **Our global payer/** stakeholder network



We continually source and vet up-to-date global payers, KOLs, and other experts through a rigorous quality assurance procedure. These are then matched to your research objectives or experts can be recruited to cater for specific projects.

# **Integrating insights** and evidence to achieve optimal market access

Our US and global expertise allows us to provide comprehensive, strategic solutions to your pricing and reimbursement challenges, boosted by a uniquely efficient form of agile stakeholder validation that informs and enhances decision-making.

Reinforced by an in-depth knowledge of the application and methodologies of US market access analytics, our integrated approach also draws support from our wider RWE and HEOR capabilities as required.

#### What our expert teams can do for you:

# ×

驪

# Market access strategy development

We identify and address key challenges and opportunities across different markets using a variety of research methods and data sources, and advise on product positioning, value demonstration, and stakeholder engagement.



### Pricing strategy and analysis

We help you set and optimize the price of your product, considering the market dynamics, payer expectations, competitor activities, and regulatory requirements, and by assessing the impact of different pricing scenarios on your revenue and profitability.



#### Payer environment assessment

We advise on the payer landscape and decision-making processes in 65+ countries through primary and secondary research, stakeholder mapping, and scenario planning. We also help you prepare for payer negotiations by providing training and coaching.

#### Stakeholder engagement

We can leverage our advanced RPR<sup>™</sup> technology, proprietary stakeholder network, and expert consulting team to validate and enhance your market access strategy at any stage of product development and commercialization.

### Join our stakeholder/payer network!



Are you an experienced healthcare decision-maker/stakeholder interested in helping patients receive cutting-edge treatments? Consider lending us your expertise at times that suit you via our online survey platform and be renumerated for your knowledge. Contact solutions@genesisrg.com.

**ACCESS & PRICING** 

# **Update!**

**Introducing enhanced US market access** data analytics

We have expanded our real-world data analytics capabilities to further support US market access strategy.

The integration of data analytics and RPR<sup>™</sup> stakeholder insights in claims analytics, contracting strategy, market assessment, patient affordability program optimization, loss of exclusivity analysis, IRA impact assessment, and healthcare policy impact, provides the validated evidence-based insights necessary for success in the US market.

# TECH Accelerate

#### RWE Maximize the value

# **Elevate your HEOR strategy** with an integrated approach

Powered by deep methodological expertise and experience across indications, we enable our clients to **innovate differently** by offering streamlined, end-to-end services that maximize the value of health economics and outcomes research (HEOR), from strategic planning to Health Technology Assessment (HTA) support and methodological specialization.

Bolstered by early strategic planning, RPR<sup>™</sup>-powered stakeholder insights, advanced technology, and an agile engagement model, we help you ask the right questions, understand the analogs, competition and policy/pricing considerations of your product via landscape assessments, and then produce rigorous findings and models that iteratively support impactful scientific communciation and value messaging.

#### ECONOMIC MODELING Transparent, fit-for-purpose modeling

Acres Acres	leth .	· Distant for 1		Barrenalis Co	. The best of the	105	
1444 100	Advantes Brantis	Medical Medical Medical	۵:		-		
	and Constant of Street			-	Reads	angunt per	
AV. 16. 1.1			101	11.40070 11.201.00	0.700	\$1,275,27 \$2,673,13 \$1,872,97	
	ESAT	E142	1074614		0.190	SERVICE SERVICE	
		14.005					
	SAUNE CR			GRAINE COST	CALCU	ATOR	-
		CH	IRONIC MI	GRAINE COST	CALCU		
	- 1 Popul	CH	RONIC MI	2 Costs	_	- Results -	
	(1) Popul Generation	CH ation	RONIC MI	2 Costs Til * (drug + administrative Istrative cost or 75	_	3 Results -	17. N
enter Look	1 Popul Generations Supportunit Existing Of Table	CH atten		Costs	0.41.e) 0.41.e	) Results -	17. N
	Endary Carl	CH Lincold S S S S S S S S S S S S S S S S S S S	-	Costs Til * (drug = admini tomat cast = 0 Telescontext Telescontext Car per venti ©	0.41.e) 0.41.e	3 Results	17. N
	Popul     September     S		Amm 148	Costs Til * (drug + admini tomat og* © Total componenties Total componenties Componentie Total	ante ante ante ante ante	() Results - Digit in Ris 	
	Constitution Const	CH ation (UKA) S S S S S S S S S S S S S		Costs Til * (drug = admini tomat cast = 0 Telescontext Telescontext Car per venti ©	anter anter anter anter	() Results - Digit in Ris 	
	Popul     Popul     Security and     Popul     Security and     Popul     Security and     Popul			Costs The <sup>16</sup> (deep + administrative Interest reserver (1) Interest reserver (1) Interest reserver (1) Index Mainty and (1) Anne (10) Anne (1)	anter) arter 225 arter 235 arter 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	() Results - Digit in Ris 	
ent of Loca i	Popular     P		Anna Star Star Star Star Star Star Star Sta	Costs     TX * (drug + admini transf range)     Status and range ()     Status and range ()     Status and range ()     Status and range ()     Status	anter anter anter anter anter anter anter anter	() Results - Digit in Ris 	
	Population     P	Che etien URAM Second Vignamic Second Vignamic Secon		Costs     TX * (bigs + advant tames rear or ()     To a second or ()     To a secon	anter) anter anter anter anter anter anter anter anter	() Results - Digit in Ris 	
	Popular     P		Anna Star Star Star Star Star Star Star Sta	Costs     Tri * (drug = admini temb reader tember reader     cost = admini tember reader     cost = reader     cost	ana	() Results - Digit in Ris 	

We have proven expertise in the design and development of all types of economic models, from cost-effectiveness models for HTA submission, to disease models, clinical trial simulations, cost calculators, and budget impact models.

Our tailored process provides you with precise control over the analytical, economic, and aesthetic framework of your simulations, resulting in transparent, scientifically rigorous and user-friendly models that perfectly align with your needs.

#### End-to-end integrated evidence planning and value demonstration

# الم الم الم

#### Strategy development

- HEOR, value and access (including pricing)
- Integrated evidence planning (IEP) Real-world evidence sourcing
- Value proposition/value story/ evidence gap analysis
- Advisorv boards
- Appraisal review/HTA/ scientific advice
- Outcomes-based contracting
- RPR stakeholder insights

#### (t3) Landscape

## assessment

- Competitive landscape analysis Pricing and reimbursement
- landscape assessment Analog assessment
- Patient Reported Outcomes (PRO) landscape
- Policy landscape
- disease state profiling

- Model adaptations
- indirect comparisons
- Preference survey

#### Scientific & value communication

scientific publications

completed across 25+

therapeutic areas

scientists and other

experts ready to

support your work

- Value dossiers
- · Tools and resources for customer-facing teams
- Response letter and submissions to HTAs
- Objection handlers
- Access playbook
- IEP playbook

#### ← RPR<sup>™</sup> Leverage our network of 3500+ payers/ strategy development

EO scientific & value communication =

generation

landscape assessment evidence

**EVIDENCE PLANNING Optimize your evidence** management and communication

An integrated evidence generation plan (IEGP) represents a cross-functional process which allows diverse functions to align on evidence generation tactics and activity. In addition to providing strategic and operational support for IEGPs across multiple therapeutic areas, we regularly develop bespoke integrated evidence planning platforms that allow HEOR product teams and stakeholders to quickly identify evidence and understand value messages.

#### **EVIDENCE SYNTHESIS Expert-led**, tech-enabled evidence synthesis

Our specialist evidence synthesis teams produce results within the most demanding of timelines to allow clients to focus on strategic interpretation.

The process is supported by EVID AI, an AI-powered literature review platform that represents the world's largest, curated, up-to-date database of healthcare literature results, and which employs machine learning to extract transparent, high quality exportable data with greater efficiency.

#### SCIENTIFIC COMMUNICATIONS Impactful communication

We have assembled a global team of **seasoned medical writers**. These experts, backed by RWE, access and pricing, and HEOR thought leaders, consistently deliver scientific communications of optimal guality and impact.

#### "Thanks for all your fantastic work. It is always a pleasure to work with you and your team."

DIRECTOR, HEOR



10

E⊘

- Disease model
- Cost calculator

#### Global patient funnel

- Meta analysis and

- Budget impact model - Cost-effectiveness Rapid evidence synthesis/

**Evidence** 

generation

Economic modeling





### POWERED BY EVIDAI

Find out more solutions@genesisrg.com www.genesisrg.com



#### Join our team

Are you passionate about delivering high quality work in a flexible, supportive environment?

Contact solutions@genesisrg.com for an informal discussion.

#### Ask us how our agile, integrated approach can help you innovate differently.

solutions@genesisrg.com | genesisrg.com +1 888-503-2680



 $\ensuremath{\mathbb{C}}$  2024 Genesis Research Group LLC. All rights reserved.